AI drug discovery startup Triana Biomedicines has emerged from stealth with USD 110 million in Series A financing led by Lightspeed Venture Partners. Other investors include Pfizer Ventures, Surveyor Capital, and Logos Capital. The company has raised USD 144.8 million since its inception in 2019.
The Massachusetts-based company will use the proceeds from the round to fuel the company’s R&D and expansion efforts.
Triana Biomedicines develops small molecule therapeutics to treat a variety of previously undruggable or poorly addressed diseases, with a focus on oncology. The company’s approach entails the discovery and development of molecular glues—a molecule that facilitates interaction between two non-interacting proteins—through its AI platform that can identify over 600 E3 ubiquitin ligases to address disease-specific targets.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.